CN110167583A - 一种治疗冠状动脉粥样硬化及其并发症的方法 - Google Patents

一种治疗冠状动脉粥样硬化及其并发症的方法 Download PDF

Info

Publication number
CN110167583A
CN110167583A CN201780078118.8A CN201780078118A CN110167583A CN 110167583 A CN110167583 A CN 110167583A CN 201780078118 A CN201780078118 A CN 201780078118A CN 110167583 A CN110167583 A CN 110167583A
Authority
CN
China
Prior art keywords
plasminogen
atherosclerosis
subject
cerebral
coronary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078118.8A
Other languages
English (en)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Talengen Institute of Life Sciences Co Ltd
Original Assignee
Talengen Institute of Life Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen Institute of Life Sciences Co Ltd filed Critical Talengen Institute of Life Sciences Co Ltd
Publication of CN110167583A publication Critical patent/CN110167583A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

本发明涉及一种用于预防和/或治疗受试者冠状动脉粥样硬化及其相关病症的方法，包括给药受试者预防和/或治疗有效量的纤溶酶原，其中所述受试者患有、怀疑患有冠状动脉粥样硬化及其相关病症或具有患上冠状动脉粥样硬化及其相关病症的风险。本发明还涉及用于预防和/或治疗受试者冠状动脉粥样硬化及其相关病症的包含纤溶酶原的药物、药物组合物、制品、试剂盒。

Description

PCT国内申请，说明书已公开。

Claims (59)

  1. PCT国内申请，权利要求书已公开。
CN201780078118.8A 2016-12-15 2017-06-19 一种治疗冠状动脉粥样硬化及其并发症的方法 Pending CN110167583A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2016110168 2016-12-15
CN2016110172 2016-12-15
CNPCT/CN2016/110168 2016-12-15
CNPCT/CN2016/110172 2016-12-15
PCT/CN2017/089044 WO2018107685A1 (zh) 2016-12-15 2017-06-19 一种治疗冠状动脉粥样硬化及其并发症的方法

Publications (1)

Publication Number Publication Date
CN110167583A true CN110167583A (zh) 2019-08-23

Family

ID=62557882

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201780078105.0A Pending CN110366425A (zh) 2016-12-15 2017-06-19 一种预防动脉粥样硬化及其并发症的方法
CN201780078127.7A Pending CN110114083A (zh) 2016-12-15 2017-06-19 一种预防和治疗脂肪肝的方法
CN201780078126.2A Pending CN110114082A (zh) 2016-12-15 2017-06-19 一种预防和治疗脂肪代谢紊乱及其相关病症的方法
CN201780078118.8A Pending CN110167583A (zh) 2016-12-15 2017-06-19 一种治疗冠状动脉粥样硬化及其并发症的方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN201780078105.0A Pending CN110366425A (zh) 2016-12-15 2017-06-19 一种预防动脉粥样硬化及其并发症的方法
CN201780078127.7A Pending CN110114083A (zh) 2016-12-15 2017-06-19 一种预防和治疗脂肪肝的方法
CN201780078126.2A Pending CN110114082A (zh) 2016-12-15 2017-06-19 一种预防和治疗脂肪代谢紊乱及其相关病症的方法

Country Status (7)

Country Link
US (4) US11478535B2 (zh)
EP (4) EP3556387A4 (zh)
JP (4) JP7214225B2 (zh)
CN (4) CN110366425A (zh)
CA (4) CA3046664C (zh)
TW (9) TW201822812A (zh)
WO (8) WO2018107685A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3391902B1 (en) * 2015-12-18 2023-10-18 Talengen International Limited Plasminogen for use in the treatment of diabetic angiocardiopathy
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
US20190314464A1 (en) 2016-12-15 2019-10-17 Talengen International Limited Novel method for treating diabetes
CA3047174A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for preventing and treating liver fibrosis
WO2018107685A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种治疗冠状动脉粥样硬化及其并发症的方法
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
CA3169325A1 (en) * 2020-02-26 2021-09-02 Jinan Li Method and drug for preventing and treating abnormal blood pressure condition
CN112056563A (zh) * 2020-09-15 2020-12-11 王胜林 用于修复脂质代谢障碍的营养素组合物及其应用
CN113041247A (zh) * 2021-04-21 2021-06-29 中山大学孙逸仙纪念医院 伊玛替尼在防治新型冠状病毒及并发症药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304383A (en) * 1990-10-11 1994-04-19 Immuno Aktiengesellschaft Pharmaceutical preparation based on Lys-plasminogen
US20050124036A1 (en) * 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
CN101918548A (zh) * 2007-11-29 2010-12-15 泰勒克里斯生物治疗学公司 重组修饰的纤溶酶
CN102482338A (zh) * 2009-07-10 2012-05-30 斯路姆基因公司 纤溶酶原和纤溶酶的变体

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4245051A (en) 1978-03-30 1981-01-13 Rockefeller University Human serum plasminogen activator
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
DE3515869A1 (de) 1985-05-03 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung optisch aktiver azolderivate
JPS62153224A (ja) 1985-12-27 1987-07-08 Green Cross Corp:The プラスミノゲン製剤
GB8721951D0 (en) 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
JP2764264B2 (ja) 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
WO1994001128A1 (en) * 1992-07-01 1994-01-20 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DK125693D0 (zh) 1993-11-05 1993-11-05 Novo Nordisk As
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
JP2002510209A (ja) 1997-06-26 2002-04-02 カロリンスカ イノベイションズ アクチボラゲット インビボで血管形成を調節することができるプラスミノーゲンのクリングルドメイン１−５
US7317003B2 (en) 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
US6465424B1 (en) 1999-02-17 2002-10-15 Bristol-Myers Squibb Company Anti-angiogenic agent and method for inhibiting angiogenesis
WO2000049871A1 (en) 1999-02-24 2000-08-31 Henry Ford Health System An anti-angiogenic kringle protein and its mutants
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US20020159992A1 (en) 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
AU2002239414A1 (en) 2000-11-02 2002-05-27 Bristol-Myers Squibb Company Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
US20070264194A1 (en) 2001-08-10 2007-11-15 The Scripps Research Institute Peptides That Bind To Atherosclerotic Lesions
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
CN1408431A (zh) 2001-09-21 2003-04-09 北京华兴生生物技术有限公司 治疗与新生血管生成相关疾病的基因工程药物
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
MXPA04007585A (es) 2002-02-06 2005-09-20 N Zyme Biotec Gmbh Metodo para la produccion de proteinas recombinantes en microorganismos.
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
JP2006507297A (ja) 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
CN1668645A (zh) 2002-05-17 2005-09-14 埃斯佩里安医疗公司 治疗缺血再灌注的方法和组合物
CN101518534A (zh) 2002-12-06 2009-09-02 法布罗根股份有限公司 脂肪调节
CN1726191A (zh) 2002-12-10 2006-01-25 惠氏公司 用作纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代的吲哚氧代－乙酰氨基乙酸衍生物
CN1451746A (zh) 2003-03-20 2003-10-29 广州市启源生物科技有限公司 人纤溶酶原Kringle 5缺失突变重组多肽
EP1666469A4 (en) 2003-09-11 2008-12-03 Inst Med Molecular Design Inc INHIBITOR OF INHIBITOR-1 PLASMOGENIC ACTIVATOR
WO2005028690A1 (en) 2003-09-24 2005-03-31 Alstom Technology Ltd Braze alloy and the use of said braze alloy
JP4740531B2 (ja) 2003-09-30 2011-08-03 雪印乳業株式会社 骨吸収抑制剤
CA2563675C (en) 2004-04-22 2012-08-28 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
US8357147B2 (en) 2005-08-17 2013-01-22 Spinal Restoration, Inc. Method for repairing intervertebral discs
FR2882654B1 (fr) 2005-03-01 2007-04-27 Servier Lab Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
WO2006095713A1 (ja) 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤
CN101189339A (zh) 2005-03-22 2008-05-28 美得思达健康有限公司 诊断和治疗心血管疾病的递送系统和方法
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
JPWO2007111242A1 (ja) 2006-03-24 2009-08-13 ロート製薬株式会社 メタボリック症候群改善剤
EP2056865B1 (en) 2006-08-28 2013-12-25 Omnio Healer AB Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
CN101573134B (zh) 2006-08-28 2013-03-06 李季男 抗感染候选药物
JP2010506957A (ja) 2006-10-20 2010-03-04 ダウ グローバル テクノロジーズ インコーポレイティド メタボリックシンドロームを予防または処置するための水溶性セルロース誘導体の使用
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
CN101015686B (zh) 2007-02-06 2010-05-19 中国人民解放军军事医学科学院基础医学研究所 一种溶栓药物增效剂及其制备方法
US20080200387A1 (en) 2007-02-15 2008-08-21 Hua-Lin Wu Anti-angiogenic protein, composition and use thereof
AR067446A1 (es) 2007-07-11 2009-10-14 Otsuka Pharma Co Ltd Un medicamento para tratar higado graso que comprende cilostazol
AT505574B1 (de) * 2007-08-10 2009-09-15 Affiris Forschungs & Entwicklungs Gmbh Mimotope zur behandlung von atherosklerose
AU2008314979A1 (en) 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Inhibitor of PAI-1 production
US20090239868A1 (en) 2007-10-23 2009-09-24 Institute Of Medical Molecular Design, Inc. Inhibitor of pai-1 production
KR101712208B1 (ko) 2008-01-09 2017-03-03 인트렉손 코포레이션 Ｐａｉ―１ 작용의 치료학적 억제제 및 이의 사용 방법
US20090208448A1 (en) 2008-02-15 2009-08-20 Solomon Keith R Inhibition of angiogenesis
WO2010076655A1 (en) 2008-12-30 2010-07-08 Ikfe Gmbh Biomarkers for adipose tissue activity
WO2010083570A1 (en) 2009-01-23 2010-07-29 The University Of Sydney Novel metabolic disease therapy
ES2874063T3 (es) 2009-03-31 2021-11-04 Renascience Inc Inhibidor del inhibidor-1 del activador del plasminógeno
EP2424561A2 (en) 2009-04-30 2012-03-07 Catherine Blondel Methods for treating ocular conditions
HUE029550T2 (en) 2009-08-12 2017-03-28 Univ Cornell Methods of preventing or treating metabolic syndrome
CN101628113B (zh) 2009-08-18 2012-01-04 南京农业大学 蚯蚓纤溶酶抗肝纤维化的应用
CN101897925B (zh) * 2009-12-16 2015-04-29 成都百康医药工业药理毒理研究院 一种治疗代谢综合症的药物组合物
US20120114652A1 (en) 2010-05-03 2012-05-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
US9044458B2 (en) * 2010-08-09 2015-06-02 The Johns Hopkins University Inhibition of tat activating regulatory DNA-binding protein 43
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
KR20140015289A (ko) 2011-01-05 2014-02-06 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민 변이체
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
US9078904B2 (en) * 2011-02-10 2015-07-14 Trustees Of Dartmouth College Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis
SG193258A1 (en) 2011-03-03 2013-10-30 Tersus Pharmaceuticals Llc COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE
CN102199587B (zh) * 2011-03-24 2013-06-19 广东药学院 人纤溶酶原功能性突变体及其制备方法和应用
BR112013024467A2 (pt) 2011-03-30 2019-09-24 Univ Texas método e composições direcionadas para células adiposas em mamíferos
CN102188699A (zh) 2011-05-06 2011-09-21 南京农业大学 一种治疗动脉粥样硬化的药物组合物及其制备方法和应用
US20120058537A1 (en) 2011-07-27 2012-03-08 Fereidoun Mahboudi Chimeric truncated and mutant variant of tissue plasminogen activator (t-pa) resistant to plasminogen activator inhibitor-1
RU2604810C2 (ru) 2011-08-12 2016-12-10 Тромбодженикс Н.В. Варианты плазминогена и плазмина
CN102532326B (zh) 2011-11-18 2017-06-09 南京大学 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用
CN103656630B (zh) 2012-09-11 2015-07-08 江苏仁寿药业有限公司 一种提纯动物药材中纤溶酶并制备成中药组合物的方法
US9718760B2 (en) * 2012-10-31 2017-08-01 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 inhibitors and methods of use thereof
US9134326B2 (en) 2013-03-14 2015-09-15 Battelle Memorial Institute Biomarkers for liver fibrosis
TWI689490B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
EP2976321A1 (en) * 2013-03-20 2016-01-27 Elevance Renewable Sciences, Inc. Acid catalyzed oligomerization of alkyl esters and carboxylic acids
CN104274449A (zh) 2013-07-11 2015-01-14 无锡信达医疗器械有限公司 治疗肥胖症的药物组合物
ES2770507T3 (es) 2013-08-13 2020-07-01 Sanofi Sa Anticuerpos dirigidos contra el inhibidor de los activadores del plasminógeno de tipo 1 (PAI-1) y usos de los mismos
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
US20160199466A1 (en) 2013-08-20 2016-07-14 Trustees Of Dartmouth College Methods For Treating Tissue Fibrosis
JP6805162B2 (ja) 2014-12-19 2020-12-23 プロメティック・バイオセラピューティクス・インコーポレイテッドＰｒｏＭｅｔｉｃ ＢｉｏＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プラミノーゲンを含む医薬組成物及びその使用
TWI801331B (zh) 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
EP3391901B1 (en) 2015-12-18 2023-07-05 Talengen International Limited Plasminogen for use in treating liver tissue damage
JP6749412B2 (ja) 2015-12-18 2020-09-02 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病性神経損傷及びその関連疾患を予防または治療するための方法
CN108463240A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗糖尿病性视网膜病变的方法
EP3391902B1 (en) 2015-12-18 2023-10-18 Talengen International Limited Plasminogen for use in the treatment of diabetic angiocardiopathy
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
DK3395359T3 (da) 2015-12-18 2024-01-15 Talengen Int Ltd Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
WO2018107685A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种治疗冠状动脉粥样硬化及其并发症的方法
TW201904990A (zh) 2017-06-23 2019-02-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304383A (en) * 1990-10-11 1994-04-19 Immuno Aktiengesellschaft Pharmaceutical preparation based on Lys-plasminogen
US20050124036A1 (en) * 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
CN101918548A (zh) * 2007-11-29 2010-12-15 泰勒克里斯生物治疗学公司 重组修饰的纤溶酶
CN102482338A (zh) * 2009-07-10 2012-05-30 斯路姆基因公司 纤溶酶原和纤溶酶的变体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BUTERA D等: "plasminogen isoform 1 precursor [Homo sapiens]", 《GENBANK》 *
C.DANESE等: "Lipoproteina(a)e plasminogeno nella malattia aterosclerotica", 《MINERVA CARDIOANGIOLOGICA》 *
QING XIAO等: "Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis", 《PROC. NAT. ACAD. SCI. USA》 *
尹桂芝等: "人纤溶酶原Kringle5区的基因克隆的表达及纯化", 《上海第二医科大学学报》 *

Also Published As

Publication number Publication date
WO2018107684A1 (zh) 2018-06-21
US20190328850A1 (en) 2019-10-31
TW201822810A (zh) 2018-07-01
TW201822805A (zh) 2018-07-01
TW201822806A (zh) 2018-07-01
JP2020510627A (ja) 2020-04-09
WO2018107692A1 (zh) 2018-06-21
JP7161217B2 (ja) 2022-10-26
WO2018107685A1 (zh) 2018-06-21
TWI684459B (zh) 2020-02-11
EP3556394A4 (en) 2020-11-25
EP3556391A4 (en) 2020-09-09
EP3556387A4 (en) 2020-09-09
TW201822812A (zh) 2018-07-01
WO2018107687A1 (zh) 2018-06-21
US20200078449A1 (en) 2020-03-12
CA3046664A1 (en) 2018-06-21
JP2020511416A (ja) 2020-04-16
CN110366425A (zh) 2019-10-22
US20200085920A1 (en) 2020-03-19
TWI680764B (zh) 2020-01-01
TW201822809A (zh) 2018-07-01
CA3046664C (en) 2024-01-02
TW202123963A (zh) 2021-07-01
CA3047169A1 (en) 2018-06-21
JP7214225B2 (ja) 2023-01-30
US11478535B2 (en) 2022-10-25
WO2018107688A1 (zh) 2018-06-21
CN110114082A (zh) 2019-08-09
EP3556387A1 (en) 2019-10-23
CN110114083A (zh) 2019-08-09
TWI746580B (zh) 2021-11-21
EP3556391A1 (en) 2019-10-23
JP2020502154A (ja) 2020-01-23
WO2018107691A1 (zh) 2018-06-21
US11547746B2 (en) 2023-01-10
EP3556393A1 (en) 2019-10-23
CA3047168A1 (en) 2018-06-21
TW201822799A (zh) 2018-07-01
WO2018107686A1 (zh) 2018-06-21
EP3556393A4 (en) 2020-11-25
TWI750189B (zh) 2021-12-21
TW201822791A (zh) 2018-07-01
EP3556394A1 (en) 2019-10-23
JP2020502156A (ja) 2020-01-23
CA3047167A1 (en) 2018-06-21
WO2018107690A1 (zh) 2018-06-21
US20190351033A1 (en) 2019-11-21
JP7160351B2 (ja) 2022-10-25
JP7158740B2 (ja) 2022-10-24
TW201822792A (zh) 2018-07-01

Similar Documents

Publication Publication Date Title
CN110167583A (zh) 一种治疗冠状动脉粥样硬化及其并发症的方法
CN108778320A (zh) 一种预防和治疗心血管病的新方法
CN108210906A (zh) 治疗冠状动脉粥样硬化及其并发症的药物及其用途
CN110121358A (zh) 一种预防和治疗肺纤维化的方法
CN110114079A (zh) 一种预防和治疗肥胖症的方法和药物
CN110114081A (zh) 一种改善心脏病变的方法
TWI746581B (zh) 纖溶酶原在製備預防和治療脂質腎損傷之藥劑上的用途
TW202123962A (zh) 一種預防和治療腎纖維化的方法
CN108463236A (zh) 一种预防或治疗放射性和化学性损伤的方法
CN108210909A (zh) 预防和治疗脂质肾损伤的药物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination